A new visiongain report forecasts that the worldwide NSCLC drugs market will generate $8.8 billion in 2019. That revenue forecast and others appear in Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025, published in October 2015. Visiongain is a business information publisher and consultancy in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “NSCLC forms one of the most dynamic markets in the oncology sector, and its treatment has been revolutionised in the past few years. The study of specific genetic mutations has led to the development of targeted therapies that offer new hope for the treatment of late-stage disease.

However, the market is facing patent expiries for various leading therapies over the forecast period and the looming threat of generic erosion, amongst other challenges. It will need to rely on its strong and varied R&D pipeline, the growth of EGFR and ALK inhibitors and the rise of immunotherapies to combat this erosion and maintain growth. As such, 2015-2025 is a crucial period for this lucrative market – one that will decide its long-term future.”

Visiongain’s study discusses the drivers that will stimulate revenue growth over the next ten years, as well as the factors that will restrain it. Those forces include the ageing population around the world, development of new targeted therapies and unmet treatment needs for the squamous form. Forces stimulating that industry include generic competition for many leading drugs, declining national healthcare budgets and resistance to therapies.

That investigation gives revenue predictions to 2025 at overall world market, submarket, product and national level.

First that work provides revenue forecasts to 2025 for 11 leading drugs:

• Alimta (pemetrexed) by Eli Lilly
• Avastin (bevacizumab) by Roche
• Tarceva (erlotinib) by Roche
• Iressa (gefitinib) by AstraZeneca
• Gilotrif (afatinib) by Boehringer Ingelheim
• Xalkori (crizotinib) by Pfizer
• Abraxane (paclitaxel Protein-Bound) by Celgene
• Taxotere (docetaxel) by Sanofi
• Cyramza (ramucirumab) by Eli Lilly
• Zykadia (ceritinib) by Novartis
• Opdivo (nivolumab) by Bristol-Myers Squibb.

The report then divides its overall market into four therapeutic segments, giving revenue forecasts to 2025:

• Chemotherapy
• EGFR and ALK inhibitors
• VEGF and VEGFR agents
• Immunotherapy.

That study also assesses the status of nine promising candidates in the R&D pipeline, discussing that progress.

The work also gives revenue forecasts to 2025 for 11 national NSCLC drug markets:

• The United States
• Japan
• Germany, France, the United Kingdom, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.